Log In
Print
BCIQ
Print
Print this Print this
 

ribavirin elaidate (TRX-201) (formerly CP-4033)

  Manage Alerts
Collapse Summary General Information
Company Weifa ASA
DescriptionLipid Vector Technology (LVT) derivative of ribavirin which inhibits eukaryotic translation initiation factor 4E (eIF4E)
Molecular Target Eukaryotic translation initiation factor 4E (eIF4E)
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPreclinical
Standard IndicationThyroid cancer
Indication DetailsTreat aggressive thyroid cancer; Treat thyroid cancer
Regulatory Designation U.S. - Orphan Drug (Treat thyroid cancer)
Partner Translational Therapeutics Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today